An observational study in Gastrointestinal Diseases, sponsored by AstraZeneca. Completed. Per ClinicalTrials.gov, last updated 2008-02-11.
Sponsored by AstraZeneca · Observational
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. gastroenterologists) are asked to document relevant data in patients with gastrointestinal disorders.
628 studies on the registry are indexed under Gastrointestinal Diseases; 128 are open to participants now.
This study's enrollment of 16,255 is above the median of 325 across 190 observational studies indexed under Gastrointestinal Diseases.
Browse Gastrointestinal Diseases studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
gastroenterologists; specialists
Exclusion Criteria:
patients with gastrointestinal disorders who need an endoscopy.
to gain insight into the relationship between subjective gastrointestinal symptoms and findings of a laryngopharyngeal-esophagogastric endoscopy with respect to the medicinal pre-therapy;
to gain insight into the currently used treatment strategies with esomeprazole depending on endoscopic findings.
No study locations are listed for this record.
This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca